Pluristem Stock is Trading Higher After €20M Non-Dilutive Funding from European Investment Bank

  • Pluristem Therapeutics Inc PSTI has received €20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding.
  • The disbursement reflects that Pluristem has achieved a key milestone in a previously announced €50 million non-dilutive financing agreement.
  • Under the EIB agreement, Pluristem expects to receive the first tranche of funds during June 2021.
  • The proceeds of the first tranche will support R&D in Europe to advance Pluristem's proprietary regenerative cell therapy platform.
  • The first tranche of €20 million will be unsecured and payable to the EIB in a single payment five years after the disbursement, with an interest rate of 4%.
  • Following the receipt of the €20 million tranche, Pluristem will have a cash balance of more than $90 million.
  • Price Action: PSTI shares are up 6.58% at $4.05 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFinancingGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!